Corporation. Chiron developed a recombinant immunoblot assay (RJBA 1.0) as a supplemental test.
The first-generation tests have become obsolete (8) because they lacked sensitivity and specificity, and were soon replaced by second-and third-generation tests. The details of the different EIAs are given in Table 1 and of immunoblot assays in Table 2 .
Third-generation assays are more sensitive and specific for the detection of anti-HCV, and they should be the test of choice. In Canada anti-HCV test kits are available mainly from Ortho Diagnostics (New Jersey), Abbott Laboratories and Organon Teknika (The Netherlands).
The diagnosis of HCV infection depends mainly on detecting circulating antibodies to this virus. EIA 2.0 detects anti-HCV in approximately 90% of cases (9) . The third-generation EIA 3.0 is more sensitive than EIA 2.0 and the predictive positive values are 0 .52 versus 0.23 (10) . EIA 3.0 detects antibody earlier in the course of infection (11) , five to six weeks after the onset of hepatitis in 80% of patients.
Some limitations have been observed with EIA tests in that they could not differentiate among acute, chronic and past infection. In some acute cases there could be a long interval before seroconversion. In low risk groups such as blood donors, even the third-generation EIAs produce false positive results.
Most of the false positive EIA results could be resolved by supplemental testing with immunoblot assays. RJBA 3 .0 is more sensitive and specific than RJBA 2.0, and 60 to 95% of the indeterminates could be resolved by the later test (10 , 12-14) . RIBA 3 .0. Matrix l , LiaTek III) showed a poor correlation among th e three tests. Molecular assays fo r the detection of HCV infectio n: The diagnosis of chronic or acu te infection is still restricted due to th e lack of a test for the detection of vira l antigen. However. recent developm ents in the polymerase chain reaction (PCR) techniqu e h ave made it possible to detect HCV RNA in serum or p lasma ( 15-l 7).
Primers specific for 5' untranslated region (UTR) are the most sensitive because this region is h ighly conserved (15) . HCV RNA could b e detected many weeks before the appearance of anti-HCV (6) a nd in some cases this m ay be the only evidence of HCV infection. Nested PCR is the most sensitive technique for the detection of HCV RNA . In our study ( l 7) 67% of the RIBA r eactive samples were positive for HCV RNA by n ested PCR with primers from the 5' UTR . On the other hand, 100% of RIBA reactive samples from h igh risk groups such as transfused patients, h emodialysis p a tients and intra-venous drug users were PCR positive . A commercial PCR kit is available for the fast detection of HCV RNA (Amplicor HCV) from Roche Diagnostic Systems (New J ersey) . Th e Amplicor HCV test uses 5' UTR specific primers, the antisense primer is biotinylated at the 5' end, and a thermostable polymerase from Thermus thermophilus is used for both reverse transcription and PCR steps. The a mplified product is detected by hybridization to a specific n u cleic acid probe (18) . We have tried this kit a nd our prelimary data indicate that it is a useful assay for the detection of HCV RNA.
The oth er assay that is commercially available for the detection of HCV RNA is called 'branched-DNA signal amplification a ssay' (Chiron). In this case, HCV RNA is hybridized directly to synthetic oligonucleotides from the highly conserved 5' UTR and core gene of HCV immobilized on a microwell plate. Synthetic bONA a mplifier molecules and multiple copies of an alkaline-phosphatase linked probe are hybridized to the immobilized h epati tis C virus type a nd its phy logenetic relation sh ip to exis ting vatiants. J Gen V irol 1992 :73: 11 3 1-4 1. 
